Gary Remington - Publications

Affiliations: 
University of Toronto, Toronto, ON, Canada 
Area:
Pharmacology, Mental Health, Epidemiology

222 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 MacKenzie NE, Kowalchuk C, Agarwal SM, Costa-Dookhan KA, Caravaggio F, Gerretsen P, Chintoh A, Remington GJ, Taylor VH, Müeller DJ, Graff-Guerrero A, Hahn MK. Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia. Frontiers in Psychiatry. 9: 622. PMID 30568606 DOI: 10.3389/fpsyt.2018.00622  0.4
2018 Castellani LN, Wilkin J, Abela A, Benarroch L, Ahasan Z, Teo C, Wilson V, Kowalchuk C, Giacca A, Remington GJ, Hahn MK. Effects of acute olanzapine exposure on central insulin-mediated regulation of whole body fuel selection and feeding. Psychoneuroendocrinology. 98: 127-130. PMID 30142549 DOI: 10.1016/j.psyneuen.2018.07.028  0.4
2017 Kowalchuk C, Teo C, Wilson V, Chintoh A, Lam L, Agarwal SM, Giacca A, Remington GJ, Hahn MK. In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact. Journal of Psychiatry & Neuroscience : Jpn. 42: 424-431. PMID 29083297 DOI: 10.1503/jpn.170092  0.4
2017 Kowalchuk C, Teo C, Wilson V, Chintoh A, Lam L, Agarwal SM, Giacca A, Remington GJ, Hahn MK. In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact. Journal of Psychiatry & Neuroscience : Jpn. 42: 170092. PMID 29035174 DOI: 10.1503/jpn.170092  0.4
2017 Miksys S, Wadji FB, Tolledo EC, Remington G, Nobrega JN, Tyndale RF. Rat brain CYP2D enzymatic metabolism alters acute and chronic haloperidol side-effects by different mechanisms. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 28454738 DOI: 10.1016/j.pnpbp.2017.04.030  0.4
2017 Fervaha G, Takeuchi H, Foussias G, Hahn MK, Agid O, Remington G. Achievement motivation in early schizophrenia: Relationship with symptoms, cognition and functional outcome. Early Intervention in Psychiatry. PMID 28230315 DOI: 10.1111/eip.12405  0.4
2016 Lister J, Andreazza AC, Navaid B, Wilson VS, Teo C, Nesarajah Y, Wilson AA, Nobrega JN, Fletcher PJ, Remington G. Lipoic Acid and Haloperidol-Induced Vacuous Chewing Movements: Implications for Prophylactic Antioxidant Use in Tardive Dyskinesia. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 27565433 DOI: 10.1016/j.pnpbp.2016.08.010  0.4
2016 Fervaha G, Caravaggio F, Mamo DC, Mulsant BH, Pollock BG, Nakajima S, Gerretsen P, Rajji TK, Mar W, Iwata Y, Plitman E, Chung JK, Remington G, Graff-Guerrero A. Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study. Psychopharmacology. PMID 27557949 DOI: 10.1007/s00213-016-4415-6  0.4
2016 Subramaniapillai M, Arbour-Nicitopoulos K, Duncan M, McIntyre RS, Mansur RB, Remington G, Faulkner G. Physical activity preferences of individuals diagnosed with schizophrenia or bipolar disorder. Bmc Research Notes. 9: 340. PMID 27405745 DOI: 10.1186/s13104-016-2151-y  0.4
2016 Fervaha G, Agid O, Takeuchi H, Foussias G, Remington G. Life satisfaction and happiness among young adults with schizophrenia. Psychiatry Research. 242: 174-179. PMID 27288735 DOI: 10.1016/j.psychres.2016.05.046  0.4
2016 Takeuchi H, Fervaha G, Lee J, Remington G. What symptom domains are associated with patient distress in schizophrenia? Schizophrenia Research. PMID 27261417 DOI: 10.1016/j.schres.2016.05.020  0.4
2016 Benarroch L, Kowalchuk C, Wilson V, Teo C, Guenette M, Chintoh A, Nesarajah Y, Taylor V, Selby P, Fletcher P, Remington GJ, Hahn MK. Atypical antipsychotics and effects on feeding: from mice to men. Psychopharmacology. PMID 27251130 DOI: 10.1007/s00213-016-4324-8  0.4
2016 Fervaha G, Takeuchi H, Foussias G, Agid O, Remington G. Using poverty of speech as a case study to explore the overlap between negative symptoms and cognitive dysfunction. Schizophrenia Research. PMID 27242067 DOI: 10.1016/j.schres.2016.05.019  0.4
2016 Oh N, See YM, Remington G, Lee J. Association Between Weight Gain and Remission Status at 3 Months in First-Episode Schizophrenia. Journal of Clinical Psychopharmacology. PMID 27187561 DOI: 10.1097/JCP.0000000000000513  0.4
2016 Lee J, Remington G. Drs Lee and Remington Reply. The Journal of Clinical Psychiatry. 77: e468. PMID 27137432 DOI: 10.4088/JCP.15lr10392a  0.4
2016 Takeuchi H, Fervaha G, Remington G. Consistency between clinician and patient ratings of clozapine-induced side effects. Schizophrenia Research. PMID 27091657 DOI: 10.1016/j.schres.2016.04.005  0.4
2016 Fervaha G, Foussias G, Takeuchi H, Agid O, Remington G. Motivational deficits in major depressive disorder: Cross-sectional and longitudinal relationships with functional impairment and subjective well-being. Comprehensive Psychiatry. 66: 31-8. PMID 26995233 DOI: 10.1016/j.comppsych.2015.12.004  0.4
2016 Taylor DL, Tiwari AK, Lieberman JA, Potkin SG, Meltzer HY, Knight J, Remington G, Müller DJ, Kennedy JL. Genetic association analysis of N-methyl-d-aspartate receptor subunit gene GRIN2B and clinical response to clozapine. Human Psychopharmacology. PMID 26876050 DOI: 10.1002/hup.2519  0.4
2016 Duncan MJ, Faulkner G, Remington G, Arbour-Nicitopoulos K. Characterizing the affective responses to an acute bout of moderate-intensity exercise among outpatients with schizophrenia. Psychiatry Research. PMID 26851964 DOI: 10.1016/j.psychres.2016.01.030  0.4
2016 Borlido C, Remington G, Graff-Guerrero A, Arenovich T, Hazra M, Wong A, Daskalakis ZJ, Mamo DC. Switching from 2 antipsychotics to 1 antipsychotic in schizophrenia: a randomized, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry. 77: e14-20. PMID 26845273 DOI: 10.4088/JCP.14m09321  0.4
2015 Behdinan T, Foussias G, Wheeler AL, Stefanik L, Felsky D, Remington G, Rajji TK, Mallar Chakravarty M, Voineskos AN. Neuroimaging predictors of functional outcomes in schizophrenia at baseline and 6-month follow-up. Schizophrenia Research. PMID 26603060 DOI: 10.1016/j.schres.2015.10.023  0.4
2015 Lam M, Abdul Rashid NA, Lee SA, Lim J, Foussias G, Fervaha G, Ruhrman S, Remington G, Lee J. Baseline social amotivation predicts 1-year functioning in UHR subjects: A validation and prospective investigation. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 26553972 DOI: 10.1016/j.euroneuro.2015.10.007  0.4
2015 Takeuchi H, Fervaha G, Remington G. Effect of Antipsychotic Dosing Regimen on Neurocognition in Schizophrenia. Journal of Clinical Psychopharmacology. 35: 728-30. PMID 26479222 DOI: 10.1097/JCP.0000000000000424  0.4
2015 Takeuchi H, Remington G. Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction. Evidence-Based Mental Health. 18: 117. PMID 26459470 DOI: 10.1136/eb-2015-102209  0.4
2015 Fervaha G, Foussias G, Takeuchi H, Agid O, Remington G. Measuring motivation in people with schizophrenia. Schizophrenia Research. PMID 26391283 DOI: 10.1016/j.schres.2015.09.012  0.4
2015 Fervaha G, Zakzanis KK, Foussias G, Agid O, Remington G. Distress related to subclinical negative symptoms in a non-clinical sample: Role of dysfunctional attitudes. Psychiatry Research. 230: 249-54. PMID 26365687 DOI: 10.1016/j.psychres.2015.09.002  0.4
2015 Remington GJ, Teo C, Wilson V, Chintoh A, Guenette M, Ahsan Z, Giacca A, Hahn MK. Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance. The Journal of Endocrinology. 227: 71-81. PMID 26330531 DOI: 10.1530/JOE-15-0074  0.4
2015 Lee J, Bies R, Bhaloo A, Powell V, Remington G. Clozapine and anemia: a 2-year follow-up study. The Journal of Clinical Psychiatry. PMID 26301364 DOI: 10.4088/JCP.14m09143  0.4
2015 Lee J, Takeuchi H, Fervaha G, Powell V, Bhaloo A, Bies R, Remington G. The Effect of Clozapine on Hematological Indices: A 1-Year Follow-Up Study. Journal of Clinical Psychopharmacology. 35: 510-6. PMID 26267420 DOI: 10.1097/JCP.0000000000000387  0.4
2015 Fervaha G, Agid O, Foussias G, Siddiqui I, Takeuchi H, Remington G. Neurocognitive impairment in the deficit subtype of schizophrenia. European Archives of Psychiatry and Clinical Neuroscience. PMID 26260899 DOI: 10.1007/s00406-015-0629-6  0.4
2015 Remington G, Seeman MV. Schizophrenia and the Influence of Male Gender Clinical Pharmacology and Therapeutics. 98: 578-581. PMID 26260896 DOI: 10.1002/cpt.201  0.4
2015 Fervaha G, Duncan M, Foussias G, Agid O, Faulkner GE, Remington G. Effort-based decision making as an objective paradigm for the assessment of motivational deficits in schizophrenia. Schizophrenia Research. 168: 483-90. PMID 26215506 DOI: 10.1016/j.schres.2015.07.023  0.4
2015 Takeuchi H, Suzuki T, Remington G, Uchida H. Antipsychotic Polypharmacy and Corrected QT Interval: A Systematic Review. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 60: 215-22. PMID 26174525  0.4
2015 Lockwood JT, Remington G. Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials. Expert Opinion On Emerging Drugs. 20: 407-21. PMID 26166007 DOI: 10.1517/14728214.2015.1050376  0.4
2015 Fervaha G, Siddiqui I, Foussias G, Agid O, Remington G. Motivation and Social Cognition in Patients with Schizophrenia. Journal of the International Neuropsychological Society : Jins. 21: 436-43. PMID 26135736 DOI: 10.1017/S1355617715000375  0.4
2015 Fervaha G, Hill C, Agid O, Takeuchi H, Foussias G, Siddiqui I, Kern RS, Remington G. Examination of the validity of the Brief Neurocognitive Assessment (BNA) for schizophrenia. Schizophrenia Research. 166: 304-9. PMID 26004693 DOI: 10.1016/j.schres.2015.05.015  0.4
2015 Fervaha G, Foussias G, Agid O, Remington G. Motivational deficits in early schizophrenia: prevalent, persistent, and key determinants of functional outcome. Schizophrenia Research. 166: 9-16. PMID 25982811 DOI: 10.1016/j.schres.2015.04.040  0.4
2015 Siu CO, Agid O, Remington G. Measuring the effects of treatment with antipsychotics. Jama Psychiatry. 72: 514-5. PMID 25945491 DOI: 10.1001/jamapsychiatry.2014.3134  0.4
2015 Lee J, Fervaha G, Takeuchi H, Powell V, Remington G. Positive symptoms are associated with clinicians' global impression in treatment-resistant schizophrenia. Journal of Clinical Psychopharmacology. 35: 237-41. PMID 25839337 DOI: 10.1097/JCP.0000000000000310  0.4
2015 Wheeler AL, Wessa M, Szeszko PR, Foussias G, Chakravarty MM, Lerch JP, DeRosse P, Remington G, Mulsant BH, Linke J, Malhotra AK, Voineskos AN. Further neuroimaging evidence for the deficit subtype of schizophrenia: a cortical connectomics analysis. Jama Psychiatry. 72: 446-55. PMID 25786193 DOI: 10.1001/jamapsychiatry.2014.3020  0.4
2015 Strassnig M, Clarke J, Mann S, Remington G, Ganguli R. Body composition, pre-diabetes and cardiovascular disease risk in early schizophrenia. Early Intervention in Psychiatry. PMID 25752319 DOI: 10.1111/eip.12225  0.4
2015 Caravaggio F, Borlido C, Hahn M, Feng Z, Fervaha G, Gerretsen P, Nakajima S, Plitman E, Chung JK, Iwata Y, Wilson A, Remington G, Graff-Guerrero A. Reduced insulin sensitivity is related to less endogenous dopamine at D2/3 receptors in the ventral striatum of healthy nonobese humans. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 18: pyv014. PMID 25716779 DOI: 10.1093/ijnp/pyv014  0.4
2015 Nakajima S, Takeuchi H, Plitman E, Fervaha G, Gerretsen P, Caravaggio F, Chung JK, Iwata Y, Remington G, Graff-Guerrero A. Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia. Schizophrenia Research. 164: 164-75. PMID 25684554 DOI: 10.1016/j.schres.2015.01.043  0.4
2015 Fervaha G, Agid O, Takeuchi H, Lee J, Foussias G, Remington G. Relationship between symptomatic improvement and overall illness severity in patients with schizophrenia. Journal of Clinical Psychopharmacology. 35: 128-33. PMID 25679125 DOI: 10.1097/JCP.0000000000000286  0.4
2015 Fervaha G, Agid O, Takeuchi H, Foussias G, Lee J, Remington G. Clinical and functional outcomes in people with schizophrenia with a high sense of well-being. The Journal of Nervous and Mental Disease. 203: 187-93. PMID 25668654 DOI: 10.1097/NMD.0000000000000266  0.4
2015 Lister J, Fletcher PJ, Nobrega JN, Remington G. Behavioral effects of food-derived opioid-like peptides in rodents: Implications for schizophrenia? Pharmacology, Biochemistry, and Behavior. 134: 70-78. PMID 25661529 DOI: 10.1016/j.pbb.2015.01.020  0.4
2015 Sinyor M, Schaffer A, Remington G. Suicide in schizophrenia: an observational study of coroner records in Toronto. The Journal of Clinical Psychiatry. 76: e98-103. PMID 25650686 DOI: 10.4088/JCP.14m09047  0.4
2015 Takeuchi H, Fervaha G, Lee J, Agid O, Remington G. Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 25: 295-302. PMID 25649680 DOI: 10.1016/j.euroneuro.2014.12.008  0.4
2015 Fervaha G, Takeuchi H, Lee J, Foussias G, Fletcher PJ, Agid O, Remington G. Antipsychotics and amotivation. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 1539-48. PMID 25567425 DOI: 10.1038/npp.2015.3  0.4
2015 Nakajima S, Takeuchi H, Fervaha G, Plitman E, Chung JK, Caravaggio F, Iwata Y, Mihashi Y, Gerretsen P, Remington G, Mulsant B, Graff-Guerrero A. Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data. Schizophrenia Research. 161: 429-33. PMID 25556080 DOI: 10.1016/j.schres.2014.12.024  0.4
2015 Foussias G, Siddiqui I, Fervaha G, Agid O, Remington G. Dissecting negative symptoms in schizophrenia: opportunities for translation into new treatments. Journal of Psychopharmacology (Oxford, England). 29: 116-26. PMID 25516370 DOI: 10.1177/0269881114562092  0.4
2015 Fervaha G, Agid O, Takeuchi H, Lee J, Foussias G, Zakzanis KK, Graff-Guerrero A, Remington G. Extrapyramidal symptoms and cognitive test performance in patients with schizophrenia. Schizophrenia Research. 161: 351-6. PMID 25471015 DOI: 10.1016/j.schres.2014.11.018  0.4
2015 Gerretsen P, Menon M, Chakravarty MM, Lerch JP, Mamo DC, Remington G, Pollock BG, Graff-Guerrero A. Illness denial in schizophrenia spectrum disorders: a function of left hemisphere dominance. Human Brain Mapping. 36: 213-25. PMID 25209949 DOI: 10.1002/hbm.22624  0.4
2014 Fervaha G, Takeuchi H, Agid O, Lee J, Foussias G, Remington G. Determinants of patient-rated and clinician-rated illness severity in schizophrenia. The Journal of Clinical Psychiatry. PMID 25562591 DOI: 10.4088/JCP.14m09128  0.4
2014 Gerretsen P, Menon M, Mamo DC, Fervaha G, Remington G, Pollock BG, Graff-Guerrero A. Impaired insight into illness and cognitive insight in schizophrenia spectrum disorders: resting state functional connectivity. Schizophrenia Research. 160: 43-50. PMID 25458571 DOI: 10.1016/j.schres.2014.10.015  0.4
2014 Gerretsen P, Remington G, Borlido C, Quilty L, Hassan S, Polsinelli G, Teo C, Mar W, Simon R, Menon M, Pothier DD, Nakajima S, Caravaggio F, Mamo DC, Rajji TK, et al. The VAGUS insight into psychosis scale--self-report and clinician-rated versions. Psychiatry Research. 220: 1084-9. PMID 25246410 DOI: 10.1016/j.psychres.2014.08.005  0.4
2014 Gorczynski P, Faulkner G, Cohn T, Remington G. Examining strategies to improve accelerometer compliance for individuals living with schizophrenia. Psychiatric Rehabilitation Journal. 37: 333-5. PMID 25243343 DOI: 10.1037/prj0000093  0.4
2014 Plitman E, Nakajima S, de la Fuente-Sandoval C, Gerretsen P, Chakravarty MM, Kobylianskii J, Chung JK, Caravaggio F, Iwata Y, Remington G, Graff-Guerrero A. Glutamate-mediated excitotoxicity in schizophrenia: a review. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 1591-605. PMID 25159198 DOI: 10.1016/j.euroneuro.2014.07.015  0.4
2014 Lee J, Takeuchi H, Fervaha G, Bhaloo A, Powell V, Remington G. Relationship between clinical improvement and functional gains with clozapine in schizophrenia. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 1622-9. PMID 25156578 DOI: 10.1016/j.euroneuro.2014.08.003  0.4
2014 Lee J, Bhaloo A, Powell V, Remington G. Therapeutic drug monitoring of clozapine: sampling error as a source of variance. Therapeutic Drug Monitoring. 36: 829-31. PMID 24977382 DOI: 10.1097/FTD.0000000000000111  0.4
2014 Lee J, Lee TS, Remington G. Schizophrenia: no health without physical health. Annals of the Academy of Medicine, Singapore. 43: 248-9. PMID 24919488  0.4
2014 Lee J, Powell V, Remington G. Mean platelet volume in schizophrenia unaltered after 1year of clozapine exposure. Schizophrenia Research. 157: 134-6. PMID 24906221 DOI: 10.1016/j.schres.2014.04.038  0.4
2014 Lee J, Takeuchi H, Remington G. Comparing dopamine D(2) receptor occupancies for use in clinical practice: attractive proposition but fraught with pitfalls. Journal of Clinical Psychopharmacology. 34: 530-2. PMID 24875070 DOI: 10.1097/JCP.0000000000000149  0.4
2014 Fervaha G, Foussias G, Agid O, Remington G. Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia Acta Psychiatrica Scandinavica. 130: 290-299. PMID 24850369 DOI: 10.1111/acps.12289  0.4
2014 Fervaha G, Agid O, McDonald K, Foussias G, Remington G. Daily activity patterns in remitted first-episode schizophrenia. Comprehensive Psychiatry. 55: 1182-7. PMID 24813789 DOI: 10.1016/j.comppsych.2014.04.001  0.4
2014 Lister J, Nobrega JN, Fletcher PJ, Remington G. Oxidative stress and the antipsychotic-induced vacuous chewing movement model of tardive dyskinesia: evidence for antioxidant-based prevention strategies. Psychopharmacology. 231: 2237-49. PMID 24752659 DOI: 10.1007/s00213-014-3582-6  0.4
2014 Fervaha G, Agid O, Takeuchi H, Foussias G, Remington G. Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: findings from the NIMH CATIE study. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 1078-85. PMID 24726579 DOI: 10.1016/j.euroneuro.2014.03.001  0.4
2014 Fervaha G, Foussias G, Siddiqui I, Agid O, Remington G. Abbreviated quality of life scales for schizophrenia: comparison and utility of two brief community functioning measures. Schizophrenia Research. 154: 89-92. PMID 24630140 DOI: 10.1016/j.schres.2014.02.013  0.4
2014 Remington G, Foussias G, Fervaha G, Agid O. Schizophrenia, cognition, and psychosis. Jama Psychiatry. 71: 336-7. PMID 24599240 DOI: 10.1001/jamapsychiatry.2013.3532  0.4
2014 Fervaha G, Agid O, Foussias G, Remington G. Toward a more parsimonious assessment of neurocognition in schizophrenia: a 10-minute assessment tool. Journal of Psychiatric Research. 52: 50-6. PMID 24507885 DOI: 10.1016/j.jpsychires.2014.01.009  0.4
2014 Guenette MD, Chintoh A, Remington G, Hahn M. Atypical antipsychotic-induced metabolic disturbances in the elderly. Drugs & Aging. 31: 159-84. PMID 24477569 DOI: 10.1007/s40266-014-0152-x  0.4
2014 Remington G, Fervaha G, Foussias G, Agid O, Turrone P. Antipsychotic dosing: found in translation. Journal of Psychiatry & Neuroscience : Jpn. 39: 223-31. PMID 24467943 DOI: 10.1503/jpn.130191  0.4
2014 Lee J, Remington G. Adequate dosing for second-generation antipsychotics in establishing treatment resistance in schizophrenia. The American Journal of Psychiatry. 171: 118-9. PMID 24399431 DOI: 10.1176/appi.ajp.2013.13070965  0.4
2014 Remington G, Hahn M. Off-label antipsychotic use and tardive dyskinesia in at-risk populations: new drugs with old side effects. Journal of Psychiatry & Neuroscience : Jpn. 39: E1-2. PMID 24359929 DOI: 10.1503/jpn.130222  0.4
2014 Rao NP, Remington G. Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials. Expert Opinion On Pharmacotherapy. 15: 373-83. PMID 24354659 DOI: 10.1517/14656566.2014.873790  0.4
2014 Fervaha G, Agid O, Foussias G, Remington G. Effect of intrinsic motivation on cognitive performance in schizophrenia: a pilot study. Schizophrenia Research. 152: 317-8. PMID 24333003 DOI: 10.1016/j.schres.2013.11.037  0.4
2014 Foussias G, Agid O, Fervaha G, Remington G. Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 693-709. PMID 24275699 DOI: 10.1016/j.euroneuro.2013.10.017  0.4
2014 Hahn MK, Chintoh A, Remington G, Teo C, Mann S, Arenovich T, Fletcher P, Lam L, Nobrega J, Guenette M, Cohn T, Giacca A. Effects of intracerebroventricular (ICV) olanzapine on insulin sensitivity and secretion in vivo: an animal model. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 448-58. PMID 24001874 DOI: 10.1016/j.euroneuro.2013.07.011  0.4
2014 Gorczynski P, Faulkner G, Cohn T, Remington G. Examining the efficacy and feasibility of exercise counseling in individuals with schizophrenia: A single-case experimental study Mental Health and Physical Activity. 7: 191-197. DOI: 10.1016/j.mhpa.2014.04.002  0.4
2014 Fervaha G, Foussias G, Agid O, Remington G. Impact of primary negative symptoms on functional outcomes in schizophrenia European Psychiatry. DOI: 10.1016/j.eurpsy.2014.01.007  0.4
2013 Zawadzki JA, Girard TA, Foussias G, Rodrigues A, Siddiqui I, Lerch JP, Grady C, Remington G, Wong AH. Simulating real world functioning in schizophrenia using a naturalistic city environment and single-trial, goal-directed navigation. Frontiers in Behavioral Neuroscience. 7: 180. PMID 24324418 DOI: 10.3389/fnbeh.2013.00180  0.4
2013 Siu CO, Agid O, Remington G. Efficacy of antipsychotic drugs for schizophrenia. Lancet (London, England). 382: 1874. PMID 24315169 DOI: 10.1016/S0140-6736(13)62616-1  0.4
2013 Fervaha G, Agid O, Takeuchi H, Foussias G, Remington G. Clinical determinants of life satisfaction in chronic schizophrenia: data from the CATIE study. Schizophrenia Research. 151: 203-8. PMID 24183751 DOI: 10.1016/j.schres.2013.10.021  0.4
2013 Hahn MK, Wolever TM, Arenovich T, Teo C, Giacca A, Powell V, Clarke L, Fletcher P, Cohn T, McIntyre RS, Gomes S, Chintoh A, Remington GJ. Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls. Journal of Clinical Psychopharmacology. 33: 740-6. PMID 24100786 DOI: 10.1097/JCP.0b013e31829e8333  0.4
2013 Farooq S, Agid O, Foussias G, Remington G. Using treatment response to subtype schizophrenia: proposal for a new paradigm in classification. Schizophrenia Bulletin. 39: 1169-72. PMID 24045038 DOI: 10.1093/schbul/sbt137  0.4
2013 Fervaha G, Foussias G, Agid O, Remington G. Neural substrates underlying effort computation in schizophrenia. Neuroscience and Biobehavioral Reviews. 37: 2649-65. PMID 24035741 DOI: 10.1016/j.neubiorev.2013.09.001  0.4
2013 Fervaha G, Agid O, Takeuchi H, Foussias G, Remington G. Life satisfaction among individuals with schizophrenia in the Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) study. The American Journal of Psychiatry. 170: 1061-2. PMID 24030617 DOI: 10.1176/appi.ajp.2013.13010060  0.4
2013 Zai CC, Tiwari AK, Mazzoco M, de Luca V, Müller DJ, Shaikh SA, Lohoff FW, Freeman N, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Kennedy JL. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. Journal of Psychiatric Research. 47: 1760-5. PMID 24018103 DOI: 10.1016/j.jpsychires.2013.07.025  0.4
2013 Fervaha G, Agid O, Foussias G, Remington G. Impairments in both reward and punishment guided reinforcement learning in schizophrenia. Schizophrenia Research. 150: 592-3. PMID 24016724 DOI: 10.1016/j.schres.2013.08.012  0.4
2013 Chan LF, Zai C, Monda M, Potkin S, Kennedy JL, Remington G, Lieberman J, Meltzer HY, De Luca V. Role of ethnicity in antipsychotic-induced weight gain and tardive dyskinesia: genes or environment? Pharmacogenomics. 14: 1273-81. PMID 23930674 DOI: 10.2217/pgs.13.127  0.4
2013 Fervaha G, Foussias G, Agid O, Remington G. Amotivation and functional outcomes in early schizophrenia. Psychiatry Research. 210: 665-8. PMID 23911005 DOI: 10.1016/j.psychres.2013.07.024  0.4
2013 Agid O, Siu CO, Potkin SG, Kapur S, Watsky E, Vanderburg D, Zipursky RB, Remington G. Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010. The American Journal of Psychiatry. 170: 1335-44. PMID 23896810 DOI: 10.1176/appi.ajp.2013.12030315  0.36
2013 Fervaha G, Remington G. Invalid responding in questionnaire-based research: implications for the study of schizotypy. Psychological Assessment. 25: 1355-60. PMID 23815113 DOI: 10.1037/a0033520  0.4
2013 Takeuchi H, Remington G. A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder. Psychopharmacology. 228: 175-85. PMID 23736279 DOI: 10.1007/s00213-013-3154-1  0.4
2013 Guenette MD, Powell V, Johnston K, Foussias G, Agid O, Hahn M, Takeuchi H, Remington G. Risk of neutropenia in a clozapine-treated elderly population. Schizophrenia Research. 148: 183-5. PMID 23727216 DOI: 10.1016/j.schres.2013.05.001  0.4
2013 Agid O, Schulze L, Arenovich T, Sajeev G, McDonald K, Foussias G, Fervaha G, Remington G. Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 23: 1017-22. PMID 23706529 DOI: 10.1016/j.euroneuro.2013.04.010  0.4
2013 Rao NP, Remington G. Investigational drugs for schizophrenia targeting the dopamine receptor: Phase II trials Expert Opinion On Investigational Drugs. 22: 881-894. PMID 23639138 DOI: 10.1517/13543784.2013.795945  0.4
2013 Hahn MK, Cohn T, Teo C, Remington G. Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters. Clinical Schizophrenia & Related Psychoses. 6: 186-96. PMID 23302448 DOI: 10.3371/CSRP.HACO.01062013  0.4
2013 Fervaha G, Remington G. Validation of an abbreviated quality of life scale for schizophrenia European Neuropsychopharmacology. 23: 1072-1077. PMID 23235268 DOI: 10.1016/j.euroneuro.2012.11.009  0.4
2013 Fervaha G, Remington G. Neuroimaging findings in schizotypal personality disorder: A systematic review Progress in Neuro-Psychopharmacology and Biological Psychiatry. 43: 96-107. PMID 23220094 DOI: 10.1016/j.pnpbp.2012.11.014  0.4
2013 Menon M, Addington J, Remington G. Examining cognitive biases in patients with delusions of reference. European Psychiatry : the Journal of the Association of European Psychiatrists. 28: 71-3. PMID 21658918 DOI: 10.1016/j.eurpsy.2011.03.005  0.4
2013 Siu CO, Agid O, Remington G. Authors' reply The Lancet. 382: 1874.  0.4
2012 Seeman P, Remington G. Antipsychotic dosing: Extended, and transient Clinical Schizophrenia and Related Psychoses. 6: 86-87. PMID 22776635 DOI: 10.3371/CSRP.6.2.6  0.4
2012 Sinyor M, Remington G. Is psychiatry ignoring suicide?: The case for clozapine Journal of Clinical Psychopharmacology. 32: 307-308. PMID 22544020 DOI: 10.1097/JCP.0b013e31825501fb  0.4
2012 Fervaha G, Remington G. Interpreting a multivariate analysis of functional neuroimaging data Frontiers in Psychiatry. 3. DOI: 10.3389/fpsyt.2012.00052  0.4
2012 Agid O, Remington G. Commentry Evidence-Based Mental Health. 15: 92. DOI: 10.1136/ebmental-2012-100906  0.4
2011 Remington G, Agid O, Foussias G. Schizophrenia as a disorder of too little dopamine: Implications for symptoms and treatment Expert Review of Neurotherapeutics. 11: 589-607. PMID 21469931 DOI: 10.1586/ern.10.191  0.4
2011 Chowdhury NI, Remington G, Kennedy JL. Genetics of antipsychotic-induced side effects and agranulocytosis Current Psychiatry Reports. 13: 156-165. PMID 21336863 DOI: 10.1007/s11920-011-0185-3  0.4
2010 Mukundan A, Faulkner G, Cohn T, Remington G. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems Cochrane Database of Systematic Reviews (Online). 12. PMID 21154372 DOI: 10.1002/14651858.CD006629  0.4
2010 Hahn MK, Remington G, Bois D, Cohn T. Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects. Journal of Clinical Psychopharmacology. 30: 706-10. PMID 21105286 DOI: 10.1097/JCP.0b013e3181fab67d  0.4
2010 Agid O, Foussias G, Singh S, Remington G. Where to position clozapine: Re-examining the evidence Canadian Journal of Psychiatry. 55: 677-684. PMID 20964947  0.4
2010 Remington G, Kapur S. Antipsychotic dosing: How much but also how often? Schizophrenia Bulletin. 36: 900-903. PMID 20650931 DOI: 10.1093/schbul/sbq083  0.4
2010 Hahn MK, Cohn T, Remington G. Comment: Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain. The Annals of Pharmacotherapy. 44: 1349-50; author repl. PMID 20587740 DOI: 10.1345/aph.1M550a  0.4
2010 Agid O, Foussias G, Remington G. Long-acting injectable antipsychotics in the treatment of schizophrenia: Their role in relapse prevention Expert Opinion On Pharmacotherapy. 11: 2301-2317. PMID 20586707 DOI: 10.1517/14656566.2010.499125  0.4
2010 Remington G. Antipsychotic dosing: Still a work in progress American Journal of Psychiatry. 167: 623-625. PMID 20516160 DOI: 10.1176/appi.ajp.2010.10030302  0.4
2010 Foussias G, Remington G. Antipsychotics and schizophrenia: From efficacy and effectiveness to clinical decision-making Canadian Journal of Psychiatry. 55: 117-125. PMID 20370961  0.4
2010 Foussias G, Remington G. Negative symptoms in schizophrenia: Avolition and occam's razor Schizophrenia Bulletin. 36: 359-369. PMID 18644851 DOI: 10.1093/schbul/sbn094  0.4
2010 Remington G, Foussias G, Agid O. Progress in defining optimal treatment outcome in schizophrenia Cns Drugs. 24: 9-20. DOI: 10.2165/11530250-000000000-00000  0.4
2010 Remington G. Augmenting clozapine response in treatment-resistant schizophrenia Therapy-Resistant Schizophrenia. 26: 129-151. DOI: 10.1159/000319813  0.4
2009 Sockalingam S, Shammi C, Remington G. Treatment of clozapine-induced hypersalivation with ipratropium bromide: A randomized, double-blind, placebo-controlled crossover study Journal of Clinical Psychiatry. 70: 1114-1119. DOI: 10.4088/JCP.08m04495  0.4
2009 Remington G. Refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall ryRemington Evidence-Based Mental Health. 12: 51. DOI: 10.1136/ebmh.12.2.51  0.4
2009 Sockalingam S, Remington G. Review: Insufficient evidence to guide use of drugs for clozapine induced hypersalivation Evidence-Based Mental Health. 12: 12. DOI: 10.1136/ebmh.12.1.12  0.4
2009 Remington G. From mice to men: What can animal models tell us about the relationship between mental health and physical activity? Mental Health and Physical Activity. 2: 10-15. DOI: 10.1016/j.mhpa.2009.01.003  0.4
2008 Remington G. Alterations of dopamine and serotonin transmission in schizophrenia Progress in Brain Research. 172: 117-140. PMID 18772030 DOI: 10.1016/S0079-6123(08)00906-0  0.4
2008 Agid O, Kapur S, Remington G. Emerging drugs for schizophrenia Expert Opinion On Emerging Drugs. 13: 479-495. PMID 18764724 DOI: 10.1517/14728214.13.3.479  0.4
2008 Seeman MV, Clodman D, Remington G. Transient tardive dystonia: overview and case presentation. Journal of Psychiatric Practice. 14: 251-7. PMID 18664896 DOI: 10.1097/01.pra.0000327317.34647.28  0.4
2008 Mizrahi R, Addington J, Remington G, Kapur S. Attribution style as a factor in psychosis and symptom resolution Schizophrenia Research. 104: 220-227. PMID 18632256 DOI: 10.1016/j.schres.2008.05.003  0.4
2008 Hazra M, Mamo DC, Remington G. Adjunctive versus monotherapeutic treatment for schizophrenia: Addressing antipsychotic side effects American Journal of Psychiatry. 165: 396-397. PMID 18316434 DOI: 10.1176/appi.ajp.2007.07111738  0.4
2008 Remington G, Kapur S. The Pharmacology of Typical and Atypical Antipsychotics Drug Induced Movement Disorders: Second Edition. 55-71. DOI: 10.1002/9780470753217.ch4  0.4
2007 Sockalingam S, Shammi C, Remington G. Clozapine-induced hypersalivation: A review of treatment strategies Canadian Journal of Psychiatry. 52: 377-384. PMID 17696024  0.4
2007 Remington G. Tardive dyskinesia: Eliminated, forgotten, or overshadowed? Current Opinion in Psychiatry. 20: 131-137. PMID 17278910 DOI: 10.1097/YCO.0b013e328017f6b1  0.4
2007 Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia Cochrane Database of Systematic Reviews (Online). PMID 17253540 DOI: 10.1093/schbul/sbm022  0.4
2007 Faulkner G, Cohn T, Remington G, Irving H. Body mass index, waist circumference and quality of life in individuals with schizophrenia Schizophrenia Research. 90: 174-178. PMID 17140768 DOI: 10.1016/j.schres.2006.10.009  0.4
2006 Remington G. Schizophrenia, antipsychotics, and the metabolic syndrome: Is there a silver lining? American Journal of Psychiatry. 163: 1132-1134. PMID 16816213 DOI: 10.1176/appi.ajp.163.7.1132  0.4
2006 Saeedi H, Remington G, Christensen BK. Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood Schizophrenia Research. 85: 222-231. PMID 16679001 DOI: 10.1016/j.schres.2006.03.033  0.4
2006 Remington G, Saha A, Chong SA, Shammi C. Augmenting strategies in clozapine-resistant schizophrenia Cns Drugs. 20: 171. PMID 16478292 DOI: 10.2165/00023210-200620020-00008  0.4
2006 Faulkner G, Cohn T, Remington G. Validation of a physical activity assessment tool for individuals with schizophrenia Schizophrenia Research. 82: 225-231. PMID 16360305 DOI: 10.1016/j.schres.2005.10.020  0.4
2005 Remington G, Kapur S, Andreasen NC. Remission: What's in a name? [4] (multiple letters) American Journal of Psychiatry. 162: 2393-2394. PMID 16330612  0.4
2005 Remington G, Saha A, Chong SA, Shammi C. Augmentation strategies in clozapine-resistant schizophrenia Cns Drugs. 19: 843-872. PMID 16185094 DOI: 10.2165/00023210-200519100-00004  0.4
2005 Remington G, Shammi C, Brown PC, Tucker WM. Overstating the case about recovery? [1] (multiple letters) Psychiatric Services. 56: 1022-1023. PMID 16088024  0.4
2005 Remington G. Rational pharmacotherapy in early psychosis British Journal of Psychiatry. 187. PMID 16055813 DOI: 10.1192/bjp.187.48.s77  0.4
2005 Chung C, Remington G. Predictors and markers of clozapine response Psychopharmacology. 179: 317-335. PMID 15717209 DOI: 10.1007/s00213-005-2174-x  0.4
2005 Turrone P, Remington G, Kapur S, Nobrega JN. Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats. Biological Psychiatry. 57: 406-11. PMID 15705357 DOI: 10.1016/j.biopsych.2004.10.023  0.4
2004 Remington G, Shammi C. The use of pharmacotherapy in the prodrome of schizophrenia Cns Spectrums. 9: 579-586. PMID 15273650  0.4
2004 Chong SA, Mythily, Remington G. Tardive Dyskinesia and Iron Status [5] Journal of Clinical Psychopharmacology. 24: 235-236. PMID 15206676 DOI: 10.1097/01.jcp.0000117432.83724.6b  0.4
2004 Chue P, Stip E, Remington G, Kopala L. Switching atypical antipsychotics: A review Acta Neuropsychiatrica. 16: 301-313. DOI: 10.1111/j.0924-2708.2004.00098.x  0.4
2004 Kapur S, Sridhar N, Remington G. The newer antipsychotics: Underlying mechanisms and the new clinical realities Current Opinion in Psychiatry. 17: 115-121. DOI: 10.1097/00001504-200403000-00008  0.4
2003 Remington G. Understanding antipsychotic "atypicality": A clinical and pharmacological moving target Journal of Psychiatry and Neuroscience. 28: 275-284. PMID 12921222  0.4
2003 Kiang M, Christensen BK, Remington G, Kapur S. Apathy in schizophrenia: Clinical correlates and association with functional outcome Schizophrenia Research. 63: 79-88. PMID 12892861 DOI: 10.1016/S0920-9964(02)00433-4  0.4
2003 Turrone P, Remington G, Kapur S, Nobrega JN. Differential effects of within-day continuous vs. transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 28: 1433-9. PMID 12838271 DOI: 10.1038/sj.npp.1300233  0.4
2003 Turrone P, Remington G, Kapur S, Nobrega JN. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. Psychopharmacology. 165: 166-71. PMID 12417967 DOI: 10.1007/s00213-002-1259-z  0.4
2003 Chong SA, Mythily, Remington G. Clinical characteristics and associated factors in antipsychotic-induced akathisia of Asian patients with schizophrenia Schizophrenia Research. 59: 67-71. PMID 12413644 DOI: 10.1016/S0920-9964(02)00156-1  0.4
2002 Turrone P, Remington G, Nobrega JN. The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy? Neuroscience and Biobehavioral Reviews. 26: 361-80. PMID 12034136 DOI: 10.1016/S0149-7634(02)00008-8  0.4
2002 Cohn TA, Remington G, Kameh H. Hyperinsulinemia in psychiatric patients treated with olanzapine [2] Journal of Clinical Psychiatry. 63: 75-76. PMID 11838632  0.4
2002 Remington G. 'Atypical' antipsychotics: Where does ziprasidone fit? Expert Review of Neurotherapeutics. 2: 13-24. DOI: 10.1586/14737175.2.1.13  0.4
2002 Remington G, Kapur S. Review: Amisulpride is effective and safe for schizophrenia - Commentary Evidence-Based Mental Health. 5: 85. DOI: 10.1136/ebmh.5.3.85  0.4
2001 Remington G, Kapur S. SB-277011 GlaxoSmithKline Current Opinion in Investigational Drugs. 2: 946-949. PMID 11757796  0.4
2001 Kapur S, Remington G. Dopamine D2 receptors and their role in atypical antipsychotic action: Still necessary and may even be sufficient Biological Psychiatry. 50: 873-883. PMID 11743942 DOI: 10.1016/S0006-3223(01)01251-3  0.4
2001 Parker V, Remington G. Electroconvulsive therapy in cases of treatment-resistant psychosis [4] Canadian Journal of Psychiatry. 46: 762-763. PMID 11692983  0.4
2001 Remington G, Khramov I. Health care utilization in patients with schizophrenia maintained on atypical versus conventional antipsychotics Progress in Neuro-Psychopharmacology and Biological Psychiatry. 25: 363-369. PMID 11294482 DOI: 10.1016/S0278-5846(00)00167-6  0.4
2001 Chong SA, Remington G, Mahendran R, Chua HC. Awareness of tardive dyskinesia in Asian patients with schizophrenia. Journal of Clinical Psychopharmacology. 21: 235-7. PMID 11270922 DOI: 10.1097/00004714-200104000-00017  0.4
2001 Kapur S, Remington G. Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia Annual Review of Medicine. 52: 503-517. PMID 11160792 DOI: 10.1146/annurev.med.52.1.503  0.4
2001 Remington G, Shammi CM, Sethana R, Lawrence R. Antipsychotic dosing patterns for schizophrenia in three treatment settings Psychiatric Services. 52: 96-98. PMID 11141536 DOI: 10.1176/appi.ps.52.1.96  0.4
2001 Remington G. Intramuscular ziprasidone reduced symptoms and was well tolerated in acute psychosis: Commentary Evidence-Based Mental Health. 4: 74. DOI: 10.1136/ebmh.4.3.74  0.4
2000 Chong SA, Remington G. Clozapine augmentation: Safety and efficacy Schizophrenia Bulletin. 26: 421-440. PMID 10885641  0.4
2000 Kapur S, Wadenberg ML, Remington G. Are animal studies of antipsychotics appropriately dosed?: Lessons from the bedside to the bench Canadian Journal of Psychiatry. 45: 241-246. PMID 10779880  0.4
2000 Remington G. Schizophrenia: Building and fixing scientific models Canadian Journal of Psychiatry. 45: 239-240. PMID 10779879  0.4
2000 Remington G, Kapur S. Atypical antipsychotics: Are some more atypical than others? Psychopharmacology. 148: 3-15. PMID 10663410  0.4
2000 Remington G. Review: Zotepine was as effective as typical and other atypical antipsychotics and more effective than placebo in schizophrenia: Commentary Evidence-Based Mental Health. 3: 78. DOI: 10.1136/ebmh.3.3.78  0.4
1999 Remington G, Chong SA. Conventional versus novel antipsychotics: Changing concepts and clinical implications Journal of Psychiatry and Neuroscience. 24: 431-441. PMID 10586534  0.4
1999 Chong SA, Remington G, Tan CH. Risperidone treatment of tardive dyskinesia and dystonia [6] Journal of Clinical Psychiatry. 60: 340-341. PMID 10362448  0.4
1999 Remington G, Chong SA, Kapur S. Distinguishing change in primary and secondary negative symptoms [12] American Journal of Psychiatry. 156: 974-975. PMID 10360154  0.4
1999 Remington G, Kapur S. D2 and 5-HT2 receptor effects of antipsychotics: Bridging basic and clinical findings using PET Journal of Clinical Psychiatry. 60: 15-19. PMID 10340683  0.4
1999 Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia American Journal of Psychiatry. 156: 286-293. PMID 9989565  0.4
1998 Chong SA, Remington G. Re: Sertraline-clozapine interaction [6] Canadian Journal of Psychiatry. 43: 856-857. PMID 9806097  0.4
1998 Remington G, Kapur S, Zipursky RB. Pharmacotherapy of first-episode schizophrenia British Journal of Psychiatry. 172: 66-70. PMID 9764129  0.4
1998 Kapur S, Zipursky RB, Remington G, Meltzer H. Do loxapine plus cyproheptadine make an atypical antipsychotic? PET analysis of their dopamine D2 and serotonin2 receptor occupancy [3] (multiple letters) Archives of General Psychiatry. 55: 666-668. PMID 9672060 DOI: 10.1001/archpsyc.55.7.666  0.4
1998 Chong SA, Remington G. Ethnicity and clozapine metabolism British Journal of Psychiatry. 172: 97. PMID 9534846  0.4
1998 Remington G, Kapur S, Zipursky R. The relationship between risperidone plasma levels and dopamine D2 occupancy: A positron emission tomographic study [1] Journal of Clinical Psychopharmacology. 18: 82-83. PMID 9472848 DOI: 10.1097/00004714-199802000-00014  0.4
1998 Chong SA, Remington G. RE: Hypertension and increased serum clozapine association with clozapine and fluoxetine in combination [5] Irish Journal of Psychological Medicine. 15: 112.  0.4
1997 Shammi CM, Remington G. Clozapine-induced necrotizing colitis [8] Journal of Clinical Psychopharmacology. 17: 230-232. PMID 9169975 DOI: 10.1097/00004714-199706000-00021  0.4
1996 Iruela LM, Remington G, Adams M. Risperidone and obsessive-compulsive symptoms [7] Journal of Clinical Psychopharmacology. 16: 85-86. PMID 8834429  0.4
1996 Collins AA, Remington G, Coulter K, Birkett K. Depression in schizophrenia: A comparison of three measures Schizophrenia Research. 20: 205-209. PMID 8794511 DOI: 10.1016/0920-9964(95)00107-7  0.4
1996 Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia American Journal of Psychiatry. 153: 466-476. PMID 8599393  0.4
1996 Remington G, Bezchlibnyk-Butler K. Management of acute antipsychotic-induced extrapyramidal syndromes Cns Drugs. 5: 21-35.  0.4
1995 Remington G. Understanding schizophrenia: The impact of novel antipsychotics Canadian Journal of Psychiatry. 40. PMID 8564914  0.4
1995 Remington GJ, Adams ME. Depot neuroleptic therapy: clinical considerations. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 40: S5-11. PMID 7627927  0.4
1995 Remington GJ. The long-term treatment of schizophrenia Canadian Journal of Psychiatry. 40. PMID 7627926  0.4
1995 Remington GJ. Love without romance: The complexity of erotomanic delusions [2] Journal of Clinical Psychiatry. 56: 533-534. PMID 7592509  0.4
1994 Remington GJ, Jeffries JJ. Erotomanic delusions and electroconvulsive therapy: A case series Journal of Clinical Psychiatry. 55: 306-308. PMID 8071292  0.4
1994 Bezchlibnyk-Butler KZ, Remington GJ. Antiparkinsonian drugs in the treatment of neuroleptic-induced extrapyramidal symptoms Canadian Journal of Psychiatry. 39: 74-84. PMID 7908605  0.4
1994 Remington GJ. Novel neuroleptics in schizophrenia: Theory and clinical relevance Canadian Journal of Psychiatry. 39. PMID 7533050  0.4
1994 Remington G, Adams M. Risperidone and obsessive-compulsive symptoms Journal of Clinical Psychopharmacology. 14: 358-359. PMID 7528755  0.4
1993 Baskys A, Wang S, Remington G, Martin Wojtowicz J. Haloperidol and loxapine but not clozapine increase synaptic responses in the hippocampus European Journal of Pharmacology. 235: 305-307. PMID 8508910 DOI: 10.1016/0014-2999(93)90151-7  0.4
1993 Remington G, Pollock B, Voineskos G, Reed K, Coulter K. Acutely psychotic patients receiving high-dose haloperidol therapy Journal of Clinical Psychopharmacology. 13: 41-45. PMID 8486816  0.4
1993 Remington G, Fornazzari L, Sethna R. Placebo response in refractory tardive akathisia Canadian Journal of Psychiatry. 38: 248-250. PMID 8100184  0.4
1993 Remington GJ. Clinical considerations in the use of risperidone Canadian Journal of Psychiatry. 38. PMID 7504575  0.4
1993 Remington GJ, Book H. Discriminative validity of the borderline syndrome index Journal of Personality Disorders. 7: 312-319.  0.4
1992 Jeffries J, Bezchlibnyk-Butler K, Remington G. Amenorrhea and galactorrhea associated with fluvoxamine in a loxapine-treated patient Journal of Clinical Psychopharmacology. 12: 296-297. PMID 1527236  0.4
1991 Fornazzari L, Remington G, Jeffries J. Akathisia, porphyria and low iron [1] Canadian Journal of Psychiatry. 36: 548. PMID 1933767  0.4
1991 Cheung SW, Tang SW, Remington G. Simultaneous quantitation of loxapine, amoxapine and their 7- and 8-hydroxy metabolites in plasma by high-performance liquid chromatography Journal of Chromatography B: Biomedical Sciences and Applications. 564: 213-221. PMID 1860915 DOI: 10.1016/0378-4347(91)80083-O  0.4
1991 Fornazzari L, Ichise M, Remington G, Smith I. Rabbit syndrome, antidepressant use, and cerebral perfusion SPECT scan findings Journal of Psychiatry and Neuroscience. 16: 227-229. PMID 1786266  0.4
1991 Remington GJ, Rosenblat H. Spousal allegations of incest during transient psychotic episodes British Journal of Psychiatry. 159: 287-288. PMID 1773251  0.4
1990 Remington G, Menuck M, Schmidt P, Legault S. The remitting atypical psychoses: clinical and nosologic considerations Canadian Journal of Psychiatry. 35: 36. PMID 2317732  0.4
1990 Tang SW, Remington G, Persad E, Rosenblat R. Coadministration of a beta-adrenergic antagonist and a tricyclic antidepressant: A pilot study Psychiatry Research. 33: 101-106. PMID 2243886 DOI: 10.1016/0165-1781(90)90062-A  0.4
1990 Remington G. Free radicals and tardive dyskinesia (I:Reply) Canadian Journal of Psychiatry. 35: 283-284.  0.4
1989 Remington GJ. Sexual life events and schizophrenia Comprehensive Psychiatry. 30: 114. PMID 2924562  0.4
1989 Remington G, DaCosta G. Ethnocultural factors in resident supervision: Black supervisor and white supervisees American Journal of Psychotherapy. 43: 398-404. PMID 2817150  0.4
1989 Menuck M, Legault S, Schmidt P, Remington G. The nosologic status of the remitting atypical psychoses Comprehensive Psychiatry. 30: 53-73. PMID 2647402 DOI: 10.1016/0010-440X(89)90118-1  0.4
1989 Remington G. Pharmacotherapy of schizophrenia Canadian Journal of Psychiatry. 34: 211-220. PMID 2566367  0.4
1989 Remington GJ. Correspondence Comprehensive Psychiatry. 30: 114. DOI: 10.1016/0010-440X(89)90126-0  0.4
1988 Remington GJ. The pisa syndrome: Possible role for serotonin and noradrenaline Journal of Clinical Psychopharmacology. 8: 228-229. PMID 2897980  0.4
1984 Remington G, Jeffries JJ. The role of cerebral arteriovenous malformations in psychiatric disturbances: Case report Journal of Clinical Psychiatry. 45: 226-229. PMID 6725213  0.4
1984 Remington G, Hoffman BF. Gas sniffing as a form of substance abuse Canadian Journal of Psychiatry. 29: 31-35. PMID 6704883  0.4
1984 Remington G, Book H. Case report of de Clerembault syndrome, bipolar affective disorder, and response to lithium American Journal of Psychiatry. 141: 1285-1287. PMID 6486270  0.4
1984 Jeffries J, Remington G, Wilkins J. The question of lithium/neuroleptic toxicity Canadian Journal of Psychiatry. 29: 601-604. PMID 6150756  0.4
1979 Anisman H, Remington G, Sklar LS. Effect of inescapable shock on subsequent escape performance: catecholaminergic and cholinergic mediation of response initiation and maintenance. Psychopharmacology. 61: 107-24. PMID 108728 DOI: 10.1007/BF00426724  0.4
1978 Anisman H, DeCatanzaro D, Remington G. Escape performance following exposure to inescapable shock: Deficits in motor response maintenance Journal of Experimental Psychology: Animal Behavior Processes. 4: 197-218. DOI: 10.1037/0097-7403.4.3.197  0.4
1976 Anisman H, Kokkinidis L, Glazier S, Remington G. Differentiation of response biases elicited by scopolamine and d-amphetamine: effects on habituation. Behavioral Biology. 18: 401-17. PMID 1016178 DOI: 10.1016/S0091-6773(76)92407-X  0.4
1976 Remington G, Anisman H. Genetic and ontogenetic variations in locomotor activity following treatment with scopolamine or d amphetamine Developmental Psychobiology. 9: 579-585. PMID 1001843  0.4
1976 Remington G, Anisman H. A simple method for quantifying tremor in rodents Pharmacology, Biochemistry and Behavior. 4: 721-723. PMID 981289 DOI: 10.1016/0091-3057(76)90226-4  0.4
1974 Remington G, Anisman H. Disruptive effects of epinephrine on active avoidance behavior: Alteration by scopolamine and d-amphetamine Pharmacology, Biochemistry and Behavior. 2: 427-430. PMID 4837911 DOI: 10.1016/0091-3057(74)90092-6  0.4
Show low-probability matches.